SCHEMBL29959525

SCHEMBL29959525

O=C(Nc1cccc2ccccc12)c1cc2c(cc1Br)OCO2

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 1.00
KDM4E B2RXH2 5/20 0.55
ALDH1A1 P00352 6/20 0.53
HPGD P15428 2/20 0.53
NPSR1 Q6W5P4 2/20 0.53
MEN1 O00255 4/20 0.52
KMT2A Q03164 4/20 0.52
RAB9A P51151 4/20 0.51
NPC1 O15118 3/20 0.51
GAA P10253 2/20 0.51
POLB P06746 1/20 0.51
TSHR P16473 1/20 0.51
TP53 P04637 1/20 0.51
NFKB1 P19838 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
SMN1; SMN2 Q16637 1/20 0.51
HSD17B10 Q99714 1/20 0.49
CHRNB2 P17787 1/20 0.49
CHRNB4 P30926 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21829027 1.00 MAPT (1.00) MAPTKDM4EALDH1A1HPGDNPSR1
SCHEMBL21828975 0.82 MAPT (0.70) MAPTKDM4EALDH1A1MEN1KMT2A
SCHEMBL21829001 0.82 MAPT (0.70) MAPTKDM4EALDH1A1HPGDMEN1
SCHEMBL21828973 0.82 MAPT (0.70) MAPTKDM4EALDH1A1HPGDMEN1
SCHEMBL21828987 0.82 MAPT (0.69) MAPTKDM4EALDH1A1HPGDNPSR1
SCHEMBL21829002 0.81 MAPT (0.68) MAPTKDM4EALDH1A1HPGDMEN1
SCHEMBL21829009 0.81 MAPT (0.68) MAPTKDM4EALDH1A1HPGDNPSR1
SCHEMBL21829008 0.80 MAPT (0.67) MAPTKDM4EALDH1A1HPGDMEN1
SCHEMBL21829017 0.80 MAPT (0.67) MAPTKDM4EALDH1A1HPGDMEN1
SCHEMBL21829028 0.80 PTGS2 (0.77) MAPTKDM4EALDH1A1HPGDMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240423927-A1 COMPOSITIONS AND METHODS FOR USE IN IMMUNOTHERAPY INSTITUT CURIE (FR) 2024-12-26 US claimed
EP-4346894-A1 ADJUVANTS GlaxoSmithKline Biologicals S.A. (BE) 2024-04-10 EP claimed
EP-4326769-A1 COMPOSITIONS AND METHODS FOR USE IN IMMUNOTHERAPY Institut Curie (FR) 2024-02-28 EP claimed
WO-2022248353-A1 ADJUVANTS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2022-12-01 WO claimed
WO-2022223619-A1 COMPOSITIONS AND METHODS FOR USE IN IMMUNOTHERAPY INSTITUT CURIE (FR) 2022-10-27 WO claimed
WO-2025080869-A1 PANCREATIC CANCER IMMUNOTHERAPY USING CATIONIC LIPID AND POLYMER NANOCARRIERS FOR CO-DELIVERY OF KRAS NEOANTIGENS AND STING AND/OR OTHER IMMUNOMODULATORS TO BOOST THE CANCER IMMUNITY CYCLE AND TREAT LIVER METASTASIS THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2025-04-17 WO disclosed
US-20240423927-A1 COMPOSITIONS AND METHODS FOR USE IN IMMUNOTHERAPY INSTITUT CURIE (FR) 2024-12-26 US disclosed
EP-4346894-A1 ADJUVANTS GlaxoSmithKline Biologicals S.A. (BE) 2024-04-10 EP disclosed
EP-4326769-A1 COMPOSITIONS AND METHODS FOR USE IN IMMUNOTHERAPY Institut Curie (FR) 2024-02-28 EP disclosed
WO-2023020992-A1 NOVEL METHODS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-02-23 WO disclosed
WO-2023020994-A1 NOVEL METHODS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-02-23 WO disclosed
WO-2023020993-A1 NOVEL METHODS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2023-02-23 WO disclosed
WO-2022248353-A1 ADJUVANTS GLAXOSMITHKLINE BIOLOGICALS SA (BE) 2022-12-01 WO disclosed
WO-2022223619-A1 COMPOSITIONS AND METHODS FOR USE IN IMMUNOTHERAPY INSTITUT CURIE (FR) 2022-10-27 WO disclosed